On April 12, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago (Press release, Veracyte, APR 12, 2023, View Source [SID1234630011]). The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company’s Decipher Prostate Genomic Classifier, which helps inform treatment decisions for men with prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The volume and quality of Decipher data being presented at AUA 2023 reinforce Veracyte’s ongoing commitment to evidence-based care and to advancing our understanding of urologic cancers. We are particularly excited about new data demonstrating the real-world impact of our Decipher Prostate test on patient care and outcomes," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
Following are details of the Decipher abstracts accepted for presentation at the AUA 2023 meeting:
Date/Time:
April 28, 2023, 10:00-10:10 a.m. CT
Title:
Molecular Correlates with PSMA Expression in Prostate Cancer (#PD04-04)
Format:
Podium Session
Presenter:
Adam Weiner, M.D., UCLA Health
Location:
McCormick Place, S401C
Date/Time:
April 28, 2023, 1:00-3:00 p.m. CT
Title:
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in a Large-Scale Real-World Dataset (#MP17-02)
Format:
Moderated Poster Session
Presenter:
Michael Leapman, M.D., Yale University School of Medicine
Location:
McCormick Place, S504
Date/Time:
April 28, 2023, 1:00-3:00 p.m. CT
Title:
Development of a Longitudinal Prostate Cancer Transcriptomic and Real-World Clinical Data Linkage (#MP17-09)
Format:
Moderated Poster Session
Presenter:
Michael Leapman, M.D., Yale University School of Medicine
Location:
McCormick Place, S504
Date/Time:
April 28, 2023, 1:00-3:00 p.m. CT
Title:
Differential Transcriptomic Indicators of Potential Therapeutic Response to Targeted Therapy for AJCC IIC+ Localized Prostate Cancer With Decipher >0.95 (#MP17-01)
Format:
Moderated Poster Session
Presenter:
Eric Li, M.D., Einstein Healthcare Network
Location:
McCormick Place, S504
Date/Time:
April 29, 2023, 3:30-5:30 p.m. CT
Title:
Use of Decipher Prostate Biopsy Test in Men With Favorable Risk Disease Undergoing Conservative Management in the SEER Registry (#MP44-17)
Format:
Moderated Poster Session
Presenter:
Alec Zhu, MD, Weill Cornell Medical College
Location:
McCormick Place, S403
Date/Time:
April 30, 2023, 3:40-3:50 p.m. CT
Title:
A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients (#PD36-02)
Format:
Podium Session
Presenter:
Joep de Jong
Location:
McCormick Place, S501A
Date/Time:
April 30, 2023, 5:20-5:30 p.m. CT
Title:
Biology and performance of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline (#LBA03-12)
Format:
Podium Session
Presenter:
Andrea Necchi, M.D., Vita-Salute San Raffaele University
Location:
McCormick Place, S404A